236例慢性心力衰竭的治疗体会
摘要
慢性心力衰竭(CHF)是器质性心脏疾病发展的必然结局。也是最主要的死亡原因。随着社会经济的发展。人们生活水平的提高,心脏疾病的发病率逐年增高,慢性心力衰竭的发病率也随之逐年增高。慢性心力衰竭的治疗目的:一方面挽救患者的生命,减轻患者的症状;另一方面改善患者的病程,减少住院率,延长患者的生存时间。尽可能提高患者的生活质量。现将我院2002年6月-2008年6月住院的236例慢性心力衰竭患者的诊断治疗情况分析报道如下:
出处
《现代医药卫生》
2009年第15期2344-2345,共2页
Journal of Modern Medicine & Health
二级参考文献16
-
1[1]Macdonald PS,Hill J,Krum H.COLA Ⅱ Investigators.The impact of baseline HR and BP on the tolerability of carvedilol in the elderly:the COLA (Carvedilol Open Label Assessment) Ⅱ Study[J].Am J Cardiovasc Drugs,2006,6(6):401-405.
-
2[2]Dobre D,van Veldhuisen DJ.SENIORS Investigators.Tolerability and dose-related effects of nebivolol in elderly patients with heart failure:data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial[J].Am Heart J,2007,154 (1):109-115.
-
3[3]Willenheimer R,van Veldhuisen DJ,CIBIS Ⅲ Investigators.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) Ⅲ.Circulation,2005,112(16):2426-2435.
-
4[4]Chuen M J,MacFadyen RJ.Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure[J].Am J Cardiol,2006,98(10):1416-1417.
-
5[5]Gheorghiade M,Konstam MA,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Shortterm clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297 (12):1332-1343.
-
6[6]Konstam MA,Gheorghiade M,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial[J].JAMA,2007,297(12):1319-1331.
-
7[7]Cleland JG,Coletta AP,Clark AL.Clinical trials update from the American College of Cardiology 2007:ALPHA,EVEREST,FUSION Ⅱ,VALIDD,PARR-2,REMODEL,SPICE,COURAGE,COACH,REMADHE,pro-BNP for the evaluation of dyspnoea and THIS-diet[J].Eur J Heart Fail,2007,9(6-7):740-745.
-
8[8]Go AS,Lee WY,Yang J,et al.Statin therapy and risks for death and hospitalization in chronic heart failure[J].JAMA.2006,296(17):2105-2111.
-
9[9]Flevari P,Parissis JT,Leftheriotis D,et al.Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy[J].Am J Cardiol,2006,98(12):1641-1645.
-
10[10]Staessen JA,Li Y,Richart T.Oral renin inhibitors[J].Lancet,2006,368(9545):1449-1456.
共引文献137
-
1王桂平.心衰患者采用抗心衰药物治疗的临床观察[J].临床研究,2014,22(7):175-175. 被引量:1
-
2王健.哲学思维在心内科临床教学中的应用[J].继续医学教育,2012,26(5):33-36. 被引量:3
-
3周月明,田毅.缬沙坦治疗充血性心力衰竭39例疗效观察[J].心脑血管病防治,2004,4(5):60-61.
-
4张同文,王耕耘.缬沙坦治疗高血压左室肥厚并充血性心力衰竭35例[J].现代医药卫生,2004,20(19):2011-2011.
-
5王正忠,刘诚.螺内酯治疗冠心病慢性心力衰竭的临床疗效[J].安徽卫生职业技术学院学报,2004,3(6):31-32. 被引量:1
-
6梁留峰,李惠霞.心力衰竭治疗进展[J].现代医药卫生,2005,21(3):299-301. 被引量:1
-
7姚欢,高宇新.硝普钠、多巴胺联合微量泵给药治疗顽固性心力衰竭[J].实用临床医药杂志,2004,8(6):72-73. 被引量:1
-
8魏运旭,王吉英.卡维地洛治疗慢性心力衰竭77例临床分析[J].中原医刊,2005,32(2):20-21.
-
9李德祥.卡维地洛治疗充血性心力衰竭临床观察[J].右江民族医学院学报,2005,27(1):37-38.
-
10柴慧.螺内酯治疗充血性心力衰竭40例疗效观察[J].中西医结合心脑血管病杂志,2005,3(3):255-255.
-
1周雷.慢性心力衰竭236例治疗体会[J].内科,2009,4(3):392-394. 被引量:4
-
2王志强,曹东来,杨磊.活动平板试验诱发室性心律失常及其与预后的关系[J].医学综述,2009,15(1):137-138. 被引量:1
-
3蹇在金,刘岁丰.抗栓药物预防老年心房颤动患者血栓事件的有效性与安全性[J].中国心血管杂志,2009,14(1):22-23. 被引量:3
-
4林志斗,陈焕章.老年人心房颤动91例临床分析[J].福建医药杂志,1999,21(2):27-27.
-
5冼秀无,凌佩莹.Brugada综合征1例报告[J].右江民族医学院学报,2002,24(5):752-752. 被引量:1
-
6梁天明.胺碘酮治疗器质性心脏病室性心律失常的临床疗效[J].实用医技杂志,2004,11(08A):1442-1442.
-
7普开菊.168例心电图U波倒置临床意义分析[J].中国农村卫生,2013(04Z):124-125.
-
8李淳.糖尿病患者合并心电图Brugada波1例[J].实用医学杂志,2011,27(20):3631-3631.
-
9刘献,王吉云.特发性室性心动过速23例临床分析[J].河北医学,2001,7(9):832-833.
-
10凌佩莹.Brugada综合征1例[J].实用心电学杂志,2004,13(2):149-149.